With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly is ... Zepbound savings card program, those without employer coverage and those who are paying outside of insurance ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

This post was written by Melanie Riehl Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace. MRK and Daiichi Sankyo's patritumab ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

Shares of Eli Lilly & Co. LLY shed 1.21% to $923.71 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.54% to 5,626.02 ...

Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

STUDY SHOWS Eli Lilly said that the additional supply will help "millions of adults with obesity access the medicine they need." That includes those not eligible for the Zepbound savings card ...